Cover Image
市場調查報告書

濾泡型淋巴瘤:全球臨床實驗趨勢

Follicular Lymphoma Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 230757
出版日期 內容資訊 英文 750 Pages
訂單完成後即時交付
價格
Back to Top
濾泡型淋巴瘤:全球臨床實驗趨勢 Follicular Lymphoma Global Clinical Trials Review, H2, 2017
出版日期: 2017年08月23日 內容資訊: 英文 750 Pages
簡介

本報告提供全球濾泡型淋巴瘤治療藥臨床實驗上之相關調查,提供您各地區,各階段,各進展狀況之臨床實驗趨勢,臨床實驗主要的參與企業和有潛力藥劑資訊,及最新臨床實驗相關新聞等資料。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要5國的臨床實驗數量
    • 中南美主要5國的臨床實驗數量

G7各國臨床實驗數量:癌症治療藥臨床實驗上濾泡型淋巴瘤的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:癌症治療藥臨床實驗上濾泡型淋巴瘤的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

濾泡型淋巴瘤治療藥臨床實驗主要的參與企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4483CTIDB

GlobalData's clinical trial report, "Follicular Lymphoma Global Clinical Trials Review, H2, 2017" provides an overview of Follicular Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Follicular Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Follicular Lymphoma to Oncology Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 18
  • Clinical Trials in G7 Countries by Trial Status 19
  • Clinical Trials by E7 Countries: Proportion of Follicular Lymphoma to Oncology Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 23
  • In Progress Trials by Phase 24
  • Clinical Trials by Trial Status 25
  • Clinical Trials by End Point Status 27
  • Subjects Recruited Over a Period of Time 28
  • Clinical Trials by Sponsor Type 29
  • Prominent Sponsors 30
  • Top Companies Participating in Follicular Lymphoma Therapeutics Clinical Trials 32
  • Prominent Drugs 34
  • Latest Clinical Trials News on Follicular Lymphoma 35
  • Aug 07, 2017: Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union 35
  • Jun 24, 2017: Verastem Reports Phase 2 Long-Term Follow-Up Data for Duvelisib in Patients with Double-Refractory Follicular Lymphoma and Small Lymphocytic Lymphoma at the 22nd Congress of the European Hematology Association 35
  • Jun 23, 2017: Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma 36
  • Jun 17, 2017: Updated Data from Phase IIIb MAGNIFY Study of REVLIMID (lenalidomide) and Rituximab Combination (R2) Show Clinical Activity and Responses in Relapsed/Refractory Follicular and Marginal Zone Lymphoma 37
  • Jun 16, 2017: BeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 14th International Conference on Malignant Lymphoma and Announces Additional Planned Global Registrational Trials for BGB-3111 38
  • Jun 15, 2017: TG Therapeutics Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma 39
  • Jun 14, 2017: Celltrion Healthcare showcases data supporting the efficacy and safety of Truxima (CT-P10, biosimilar rituximab) in advanced follicular lymphoma and rheumatoid arthritis 39
  • Jun 14, 2017: Epizyme Reports Positive Interim Data from Phase 2 Trial for Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL Patients 40
  • Jun 13, 2017: TG Therapeutics Recaps Schedule of Clinical Data Presentations of TGR-1202 at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress 41
  • Jun 07, 2017: BeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference Call 41
  • Jun 05, 2017: Immune Design Updates Positive Data from Lead Immuno-oncology Product candidate, G100, at ASCO Annual Meeting 42
  • May 31, 2017: MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma 43
  • Clinical Trial Profile Snapshots 44

Appendix 747

  • Abbreviations 747
  • Definitions 747
  • Research Methodology 748
  • Secondary Research 748
  • About GlobalData 749
  • Contact Us 749
  • Disclaimer 749
  • Source 750

List of Tables

List of Tables

  • Follicular Lymphoma Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Follicular Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Follicular Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Follicular Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Follicular Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Follicular Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Follicular Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
  • Follicular Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
  • Proportion of Follicular Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2017* 17
  • Follicular Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
  • Follicular Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Proportion of Follicular Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2017* 20
  • Follicular Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Follicular Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Follicular Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2017* 23
  • Follicular Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 24
  • Follicular Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
  • Follicular Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
  • Follicular Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
  • Follicular Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29
  • Follicular Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
  • Follicular Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
  • Follicular Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34

List of Figures

List of Figures

  • Follicular Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Follicular Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Follicular Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Follicular Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Follicular Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Follicular Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Follicular Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
  • Follicular Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
  • Proportion of Follicular Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2017* 17
  • Follicular Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
  • Follicular Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Proportion of Follicular Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2017* 20
  • Follicular Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Follicular Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Follicular Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2017* 23
  • Follicular Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 24
  • Follicular Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
  • Follicular Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
  • Follicular Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
  • Follicular Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 29
  • Follicular Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
  • Follicular Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 32
  • Follicular Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34
  • GlobalData Methodology 748
Back to Top